NRG-GY031

Open to Accrual

Return to Protocol Table

A Phase IB Study Of Combination Atr (M1774) And Bet Inhibition (Zen003694) To Exploit Arid1a Loss In Recurrent Ovarian And Endometrial Cancer

Principal Investigator

Fiona Simpkins, MD,

Status

Open to Accrual

Date Opened To Accrual

August 31 2023

Disease Site

Gynecologic [GY]

Uterine Corpus

Phase

I/II

Developmental Therapeutics

Yes

Primary Objective

To determine the maximum tolerated dose (MTD) and the dose-limiting toxicities (DLTs) for combination of ATR inhibitor (M1774) and BET inhibitor (ZEN003694) in women with recurrent clear cell, endometrioid, and platinum resistant high grade serous ovarian carcinoma (HGSOC) and clear cell and endometrioid endometrial carcinoma irrespective of ARID1A status (PART I). To determine safety and tolerability in ARID1A pathogenic alteration (ARID1A^MUT) and ARID1A wildtype (ARID1A^WT) cohorts (ARID1A is an integral biomarker) in an expansion phase (PART II). To determine change in pharmacodynamic biomarker expression of ƔH2AX (for ATR inhibition, integral biomarker) from pre-treatment and on-treatment tumor samples in ARID1A^MUT and ARID1A^WT expansion cohorts by immunohistochemistry (IHC) (PART II).

Patient Population

Women with recurrent ovarian and endometrial cancer.

Target Accrual

Forms

Investigator Resources

Study Memos

Patient Study Webpage

To learn more about this study, visit the Patient Study Webpage.

Support NRG Oncology.
Help Our Cause.

We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More

Donate Today

NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.